查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010056

中樞神經系統藥物市場：2026-2032年全球市場預測（依藥物類別、劑型、目標患者、作用機制、治療領域、通路、處方格式及銷售模式分類）

Central Nervous System Drugs Market by Drug Class, Dosage Form, Patient Type, Mechanism Of Action, Therapeutic Area, Distribution Channel, Prescription Type, Sales Model - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，中樞神經系統藥物市場價值將達到 248 億美元，到 2026 年將成長至 269.3 億美元，到 2032 年將達到 494.6 億美元，複合年成長率為 10.36%。

主要市場統計數據
基準年 2025 248億美元
預計年份：2026年 269.3億美元
預測年份 2032 494.6億美元
複合年成長率 (%) 10.36%

概述不斷發展的中樞神經系統治療市場，重點關注臨床創新、患者需求和商業化促進因素。

中樞神經系統（CNS）治療領域正處於關鍵的轉折點，這主要得益於科學進步、不斷變化的監管預期以及醫療服務模式的變革。本執行摘要概述了現代CNS藥物研發和商業化所涉及的廣泛治療類別、劑型、患者群體、作用機制和通路。透過闡明這些要素之間的相互作用，讀者將更深入地了解臨床創新如何滿足未被滿足的醫療需求，以及在哪些營運或政策限制下需要採取積極主動的措施。

神經科學、治療技術和護理模式的進步如何匯聚起來，重塑中樞神經系統療法的開發、獲取和生命週期策略？

中樞神經系統疾病領域的變革性變化是由科學、技術和醫療保健系統三大領域的整合趨勢所驅動的。分子神經科學的進步以及對突觸和神經傳導物質路徑更深入的理解，正在催生新的監管靶點，從而催生出新型的在臨床實驗藥物，並改善現有療法的作用機制。以生物標記開發和分層試驗設計為基礎的精準醫療方法，使得針對異質性疾病的干涉措施更具針對性，進而重塑了臨床開發策略和監管互動。

了解不斷變化的美國關稅對中樞神經系統 (CNS) 治療藥物供應鏈的韌性、製造選擇和通路經濟的多方面影響。

近期美國主導的關稅政策對中樞神經系統（CNS）治療藥物的供應鏈、製造業經濟和策略採購決策施加了多重壓力。依賴國際供應商提供活性成分、輔料或最終製劑的公司被迫重新評估其供應商組合，並更清楚地了解其多層級的供應關係，以確保供應的連續性。這種調整往往凸顯了地理多元化和雙重採購安排的重要性，這些安排能夠有效吸收政策帶來的成本和物流衝擊。

基於藥物類別、劑型、病患群體、作用機制、治療領域、通路、處方狀態和銷售模式的詳細細分，可以實現精準的策略調整。

詳細的市場細分分析揭示了產品、患者、作用機制、治療領域、分銷管道、處方狀態和銷售模式等維度上的差異化機會和營運重點。依藥物類別分類，市場涵蓋鎮痛藥、抗憂鬱劑、抗癲癇藥、抗精神病藥、抗焦慮藥、中樞神經系統興奮劑和催眠/鎮靜藥。鎮痛藥類別進一步分為非鴉片類鎮痛藥和鴉片類鎮痛藥，每種鎮痛藥都有其獨特的臨床考慮和監管審查。抗癲癇藥物根據其作用機制分為鈣離子通道阻斷劑、GABA增強劑、麩胺酸抑制劑和鈉通道阻斷劑，這些分類為臨床前建模和臨床終點選擇提供了基礎。抗精神病藥分為非典型抗精神病藥和典型抗精神病藥，抗焦慮藥則分為苯二氮平類和非苯二氮平治療方法。中樞神經系統興奮劑以安非他命和哌甲酯製劑為特徵，而催眠藥和鎮靜劑則包括巴比妥類藥物、苯二氮平類藥物和非苯二氮平類催眠藥。了解這些藥物類別之間的差異對於臨床定位和監管風險評估至關重要。

美洲、歐洲、中東和非洲以及亞太地區的區域策略差異決定了監管策略、製造地和市場進入管道。

區域趨勢對臨床重點、監管互動、生產策略和商業性執行都有顯著影響。在美洲，市場環境受支付主導的療效預期、成熟的臨床試驗體係以及強調真實世界療效的複雜報銷結構的影響。臨床開發往往優先考慮療效比較終點和長期安全性數據，而商業策略則通常側重於與醫療管理機構談判、與專科藥房合作以及與醫生網路協作，以確保獲得處方藥資格。

創新公司、專業生物技術公司、非專利公司和生產合作夥伴為在中樞神經系統 (CNS) 治療領域獲得競爭優勢而採取的策略策略和合作方式。

在中樞神經系統 (CNS) 領域營運的主要企業展現出多元化的策略方針，這反映了它們研發管線的成熟度、商業產品組合組成和營運實力。創新公司專注於獨特的作用機制和新型給藥平台以實現臨床差異化，同時投資於真實世界數據 (REW) 項目和患者支持服務，以強化其價值提案。專業生技公司通常專注於具有高度未滿足需求的特定適應症，並可能尋求合作和許可，以加速後期開發和商業化進程。

中樞神經系統治療領域領導者面臨的實際策略挑戰：加強供應鏈韌性，使製劑創新與面向支付者的證據保持一致，並加速市場進入。

產業領導者應採取切實可行的優先事項，在科學抱負與實際可行性和市場現實之間取得平衡。首先，應透過多元化供應商關係，並對關鍵活性成分和複雜添加劑實施雙重採購，來增強供應鏈韌性。基於情境的採購規劃和合約保障措施可以減輕政策引發的干擾，並降低病患服務中斷的風險。

本文概述了調查方法結合了對專家的初步訪談、對第二手資料的系統整合以及情景主導分析，以確保對中樞神經系統 (CNS) 市場獲得可重複和可操作的見解。

本分析的調查方法結合了結構化的初步研究和全面的第二手資料，從而得出穩健且多角度的見解。初步研究活動包括對參與中樞神經系統（CNS）藥物研發和分銷的臨床專業人員、監管專家、供應鏈經理和商業負責人進行深入檢驗。透過這些對話，我們獲得了關於臨床重點、證據預期和營運限制的定性背景信息，以指南戰略決策。

透過整合強調全面臨床差異化、營運韌性和與支付方需求一致的證據產生的策略挑戰，我們確保永續進入中樞神經系統 (CNS) 市場。

整合科學進步、製劑創新、監管演變和分銷管道變革等方面的洞見，揭示出一個核心主題：中樞神經系統治療領域的成功需要整合策略，將臨床差異化與卓越運營相結合。能夠將新穎性機制轉化為對患者有意義的療效，同時確保供應連續性和與支付方協調一致的公司，將能夠創造永續的價值。反之，即使擁有臨床潛力，那些低估現代支付方和醫療服務提供者對營運和循證實踐要求的公司，也可能面臨市場准入壁壘。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 中樞神經系統藥物市場：依藥物類別分類

  • 止痛藥
    • 非鴉片類鎮痛藥
    • 鴉片類鎮痛藥
  • 抗憂鬱症
  • 抗癲癇藥物
    • 鈣離子通道阻斷劑
    • GABA增強劑
    • 麩胺酸抑制劑
    • 鈉通道阻斷劑
  • 抗精神病藥物
    • 非典型
    • 典型的
  • 抗焦慮藥物
    • 苯二氮平類藥物
    • 非苯二氮平類藥物
  • 中樞神經系統興奮劑
    • 安非他命
    • 哌甲酯
  • 催眠藥和鎮靜藥
    • 巴比妥類藥物
    • 苯二氮平類藥物
    • 非苯二氮平類催眠藥

第9章 中樞神經系統藥物市場：依劑型分類

  • 膠囊
    • 緩釋膠囊
    • 標準膠囊
  • 注射液
    • 肌肉內注射
    • IV
    • 皮下
  • 口服液
    • 懸浮液
    • 糖漿
  • 藥片
    • 延遲釋放片
    • 緩釋片
    • 標準片劑
  • 經皮貼劑
    • 矩陣補丁
    • 水庫補丁

第10章 中樞神經系統藥物市場：依病患類型分類

  • 成人版
  • 老年人
  • 兒童

第11章 中樞神經系統藥物市場：依作用機制分類

  • 膽鹼能
  • 多巴胺能
  • GABA能
  • 麩胺酸介導的
  • 去甲腎上腺素能
  • 血清素活性

第12章 中樞神經系統藥物市場：依治療領域分類

  • ADHD
  • 阿茲海默症
  • 焦慮症
  • 憂鬱症
  • 癲癇
  • 失眠
  • 偏頭痛
  • 疼痛
  • 帕金森氏症
  • 思覺失調症

第13章 中樞神經系統藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章 中樞神經系統藥物市場：依處方類型分類

  • 非處方藥
  • 處方藥

第15章 中樞神經系統藥物市場：依銷售模式分類

  • 品牌商品
  • 非專利的

第16章 中樞神經系統藥物市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章 中樞神經系統藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章 中樞神經系統藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章：美國中樞神經系統藥物市場

第20章：中國中樞神經系統藥物市場

第21章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc
  • Allergan plc
  • Amgen Inc
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc
  • Neurocrine Biosciences, Inc
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd
  • Pfizer Inc
  • Sanofi SA
  • Takeda Pharmaceutical Company Ltd
  • Teva Pharmaceutical Industries Ltd
  • UCB SA
Product Code: MRR-434CCDA05199

The Central Nervous System Drugs Market was valued at USD 24.80 billion in 2025 and is projected to grow to USD 26.93 billion in 2026, with a CAGR of 10.36%, reaching USD 49.46 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 24.80 billion
Estimated Year [2026] USD 26.93 billion
Forecast Year [2032] USD 49.46 billion
CAGR (%) 10.36%

A concise orientation to the evolving central nervous system therapeutics landscape emphasizing clinical innovation, patient needs, and commercialization drivers

The central nervous system therapeutics domain is at a pivotal juncture, shaped by converging scientific advances, evolving regulatory expectations, and shifting patterns of care delivery. This executive summary provides a focused orientation to the broad set of therapeutic classes, dosage formats, patient populations, mechanisms of action, and distribution pathways that define contemporary CNS drug development and commercialization. By clarifying how these elements interact, readers can better understand where clinical innovation aligns with unmet needs, and where operational or policy-driven constraints require proactive mitigation.

Across the spectrum from analgesics and antidepressants to antiepileptics and antipsychotics, development strategies increasingly prioritize precision, tolerability, and long-term safety. New formulations and delivery technologies seek to improve adherence and reduce systemic adverse effects, while digital health adjuncts are positioning themselves as complementary solutions for symptom tracking and behavioral interventions. Concurrently, payer expectations and real-world evidence requirements are raising the bar for demonstrating comparative effectiveness and value, influencing both clinical development plans and commercialization timelines.

The central nervous system area demands an integrated view that spans scientific mechanism, patient segmentation, and channel dynamics. This introduction sets the stage for a deeper analysis of the structural shifts reshaping the landscape, the policy changes that are altering cost and supply considerations, and the segmentation insights that inform targeted product and market strategies.

How converging advances in neuroscience, delivery technologies, and care models are reshaping development, access, and lifecycle strategies in CNS therapeutics

Transformative shifts in the central nervous system field are being driven by convergent trends across science, technology, and health systems. Advances in molecular neuroscience and an improved understanding of synaptic and neurotransmitter pathways have created novel targets for modulation, prompting new classes of investigational agents and mechanistic refinements of existing therapies. Precision approaches-rooted in biomarker development and stratified trial designs-are enabling more targeted interventions for heterogeneous conditions, and this, in turn, is reshaping clinical development strategies and regulatory engagement.

Parallel to scientific innovation, delivery science and formulation engineering are altering routes to patient access. Extended-release platforms, novel transdermal systems, and parenteral formats designed for sustained delivery are being prioritized to improve adherence and to differentiate products in crowded therapeutic categories. Digital therapeutics and connected adherence tools are increasingly integrated with drug development programs to demonstrate patient-centric outcomes and to support reimbursement discussions. These adjuncts also create opportunities for lifecycle management and new revenue models that extend beyond traditional pharmaceutical sales.

Health system evolution is redefining commercialization channels. Telemedicine expansion, remote monitoring, and pharmacy delivery models are changing how patients obtain CNS therapies and how clinicians manage long-term conditions. At the same time, regulatory frameworks and payer expectations for real-world evidence are encouraging manufacturers to plan post-authorization evidence generation earlier in development. The combined effect of these shifts is a landscape in which scientific novelty, delivery innovation, and evidence generation must be orchestrated to succeed commercially and clinically.

Understanding the multifaceted influence of evolving U.S. tariffs on supply chain resilience, manufacturing choices, and channel economics for CNS therapeutics

Recent tariff policies originating from the United States have exerted multi-dimensional pressure on CNS drug supply chains, manufacturing economics, and strategic sourcing decisions. Companies that rely on international suppliers for active pharmaceutical ingredients, excipients, or finished dosage forms have needed to reassess vendor portfolios and to increase visibility into tiered supply relationships to maintain continuity of supply. This recalibration often elevates the importance of geographic diversification and of dual sourcing arrangements that can absorb policy-induced cost and logistical shocks.

Tariff-driven cost increases affect different segments of the CNS value chain in distinct ways. Innovator companies with differentiated therapeutic offerings may be better positioned to negotiate price adjustments or to absorb marginal cost increases through value arguments, whereas generic manufacturers operating in thin-margin categories face heightened pressure to optimize production efficiency and to secure low-cost raw materials. Deliberations around onshoring certain manufacturing activities or expanding regional production capacity are now routine elements of portfolio planning conversations, especially for dosage forms that demand complex manufacturing capabilities such as extended-release oral solids or specialized injectable solutions.

In response to tariff-related disruptions, commercial teams have also scrutinized distribution strategies. Shifts in channel economics can influence decisions about the balance between hospital pharmacies, retail pharmacy networks, and online pharmacy partnerships. Moreover, regulatory and payer landscapes can compound tariff effects by influencing reimbursement dynamics and procurement sourcing policies. The net result is a heightened emphasis on scenario planning, clearer contractual protections with suppliers, and more robust supply chain governance to protect both continuity of care and commercial viability.

Deep segmentation-driven insights across drug class, formulation, patient cohort, mechanism, therapeutic area, channel, prescription status, and sales model for precise strategic alignment

A granular view of segmentation reveals differentiated opportunities and operational priorities across product, patient, mechanism, therapeutic area, channel, prescription status, and sales model dimensions. Within drug classes, the market spans analgesic, antidepressant, antiepileptic, antipsychotic, anxiolytic, CNS stimulant, and hypnotic and sedative categories. The analgesic category further divides into non-opioid and opioid analgesics, each with distinct clinical considerations and regulatory scrutiny. Antiepileptic agents cluster by mechanism into calcium channel blockers, GABA enhancers, glutamate inhibitors, and sodium channel blockers, which informs both preclinical modeling and clinical endpoint selection. Antipsychotic compounds bifurcate into atypical and typical classes, while anxiolytics are differentiated into benzodiazepine and non-benzodiazepine treatments. CNS stimulants are characterized by amphetamines and methylphenidate variants, and hypnotic and sedative modalities include barbiturates, benzodiazepines, and non-benzodiazepine hypnotics. Understanding these class-level distinctions is critical for clinical positioning and regulatory risk assessment.

Dosage form segmentation spans capsule, injectable solution, oral solution, tablet, and transdermal patch presentations. Capsules may be standard or extended-release, and injectable solutions may be administered intramuscularly, intravenously, or subcutaneously, each route carrying unique clinical use cases and supply chain implications. Oral solutions are typically provided as suspensions or syrups, whereas tablets can be formulated as delayed-release, extended-release, or standard immediate-release types. Transdermal patches are engineered as matrix or reservoir systems, and they represent an important route for improving adherence and steady-state exposure in select indications. These dosage characteristics influence development complexity, regulatory dossiers, manufacturing investments, and commercial messaging.

Patient type segmentation identifies adult, geriatric, and pediatric populations, underscoring the need for age-appropriate formulations, dosing strategies, and safety monitoring. Mechanism of action segmentation highlights cholinergic, dopaminergic, GABAergic, glutamatergic, noradrenergic, and serotonergic approaches, providing a framework for biomarker selection and for therapeutic differentiation. Therapeutic area segmentation includes ADHD, Alzheimer's disease, anxiety, depression, epilepsy, insomnia, migraine, pain, Parkinson's disease, and schizophrenia; each area brings distinct endpoints, comorbidity profiles, and stakeholder expectations that shape both clinical development and market access pathways. Distribution channel segmentation-hospital pharmacy, online pharmacy, and retail pharmacy-affects fulfillment strategies, patient support programs, and reimbursement alignment. Prescription type segmentation differentiates over-the-counter from prescription products, which has implications for regulatory classification and consumer marketing. Sales model segmentation separates branded from generic offerings, determining the intensity of promotional activity, pricing flexibility, and lifecycle extension tactics. Together, these segmentation lenses create a matrix that decision-makers can use to align R&D priorities, manufacturing investments, and commercial tactics with distinct patient and market needs.

Regional strategic differences across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory strategy, manufacturing location, and market access pathways

Regional dynamics materially influence clinical priorities, regulatory engagement, manufacturing strategy, and commercial execution. In the Americas, the market environment is shaped by payer-driven outcomes expectations, a mature clinical trial ecosystem, and a complex reimbursement architecture that privileges demonstrable real-world effectiveness. Clinical development tends to emphasize comparative effectiveness endpoints and long-term safety data, while commercial strategies often concentrate on managed care negotiations, specialty pharmacy partnerships, and physician network engagement to secure formulary placement.

In Europe, Middle East & Africa, regulatory diversity and heterogeneous procurement systems create a mosaic of access considerations. Countries within this wider region exhibit varying degrees of centralized assessment versus decentralized procurement, and manufacturers need differentiated market access dossiers to address national HTA processes and local pricing negotiations. In addition, regional manufacturing hubs and strategic partnerships with contract manufacturers can be instrumental for market entry and for managing cross-border supply chain risks. Clinical development plans often incorporate multi-jurisdictional requirements early to streamline approvals and reimbursement discussions.

In Asia-Pacific, strong growth in clinical trial activity, rising investment in biomanufacturing, and increasing digital health adoption are notable. Local regulatory authorities are enhancing capabilities and streamlining pathways for innovative therapies, and governments are investing in domestic production capacity for critical therapeutics. Distribution channel innovation-especially rapid expansion of online pharmacy models and telehealth services-shapes access pathways for chronic CNS conditions. Together, these regional characteristics should inform manufacturing location decisions, regulatory engagement sequencing, and tailored commercial models that reflect payers, prescribers, and patient behavior in each geography.

Strategic playbooks and collaborative approaches adopted by innovators, specialty biotechs, generics, and manufacturing partners to gain competitive advantage in CNS therapies

Key companies operating in the central nervous system space demonstrate a range of strategic postures that reflect their pipeline maturity, commercial portfolio composition, and operational strengths. Innovator firms emphasize differentiated mechanisms of action and novel delivery platforms to establish clinical differentiation, while also investing in real-world evidence programs and patient support services to substantiate value propositions. Specialty biotechs often focus on narrow indications with high unmet need and may pursue partnerships or licensing to accelerate late-stage development and commercialization.

Generic and contract manufacturing organizations are concentrating on scale, cost optimization, and flexible manufacturing capabilities to meet demand for established formulation types and to support rapid fill-and-finish needs. These players also explore opportunities to manufacture complex modified-release products and transdermal systems as a route to capture higher-value manufacturing contracts. At the intersection of therapeutic and technology innovation, digital health companies and platform providers are collaborating with pharmaceutical firms to integrate adherence tracking, remote monitoring, and outcome measurement into product value chains, facilitating new evidence generation pathways that support reimbursement dialogues.

Across company types, effective strategies include targeted alliance formation with academic centers and clinical networks to access specialized patient populations, early engagement with regulatory authorities to clarify evidentiary expectations, and disciplined lifecycle management to extend product relevance through formulation improvements or label expansions. Firms that align R&D priorities with pragmatic commercial execution plans and robust supply chain governance are best positioned to navigate the complexity of CNS markets.

Practical strategic imperatives for leaders to bolster supply chain resilience, align formulation innovation with payer evidence, and accelerate market access in CNS therapeutics

Industry leaders should pursue a set of actionable priorities that balance scientific ambition with operational pragmatism and market realism. First, strengthen supply chain resilience by diversifying supplier relationships and incorporating dual sourcing for critical active ingredients and complex excipients. Scenario-based procurement planning and contractual protections can mitigate policy-driven disruptions and reduce the risk of service interruptions for patients.

Second, invest strategically in dosage form innovation that aligns with adherence and safety imperatives. Extended-release formulations, transdermal systems, and patient-friendly oral solutions can differentiate products in competitive categories and support improved clinical outcomes. Product teams should align these formulation choices with payer evidence needs and with pragmatic manufacturing pathways that control complexity and time to market.

Third, design development programs that integrate real-world evidence generation from the outset. Early planning for pragmatic trials, registry-based outcome collection, and post-authorization safety studies can accelerate reimbursement discussions and strengthen clinical value claims. Fourth, prioritize targeted market access strategies by engaging payers and health technology assessment bodies early to understand evidence thresholds and to co-design outcome measures that matter for coverage decisions.

Fifth, pursue partnerships across the ecosystem-including academic centers, digital health firms, and experienced contract development organizations-to fill capability gaps and to accelerate time-to-market. Finally, execute a differentiated commercial strategy that tailors messaging and channel mix to patient segments and provider workflows, leveraging specialty pharmacy capabilities where appropriate and embracing online pharmacy channels to meet evolving patient preferences.

Methodological overview combining primary expert interviews, systematic secondary synthesis, and scenario-driven analysis to ensure reproducible and actionable CNS market insights

The research methodology behind this analysis combines structured primary inquiry with comprehensive secondary synthesis to produce robust, triangulated insights. Primary research activities included in-depth interviews with clinical experts, regulatory specialists, supply chain managers, and commercial leaders involved in central nervous system drug development and distribution. These conversations provided qualitative context around clinical priorities, evidentiary expectations, and operational constraints that inform strategic decision-making.

Secondary research involved systematic review of peer-reviewed literature, clinical trial registries, regulatory guidance, public company disclosures, and industry conference materials. Data were cross-validated across multiple public and proprietary sources to reduce bias and to ensure consistency of interpretation. The study also integrated case-based analyses of recent product launches and regulatory interactions to surface practical lessons that are relevant across therapeutic classes and dosage forms.

Analytic techniques included thematic synthesis to identify cross-cutting trends, scenario planning to explore the implications of policy and supply chain shifts, and gap analysis to expose unmet clinical and commercial needs. Quality control measures included peer review by subject matter experts and reconciliation of divergent perspectives through iterative validation. The methodology emphasizes transparency, reproducibility, and pragmatic interpretation so that findings can be directly applied to portfolio planning, due diligence, and market entry strategy.

Synthesis of strategic imperatives emphasizing integrated clinical differentiation, operational resilience, and payer-aligned evidence generation to secure durable CNS market access

The combined insights from scientific advances, formulation innovation, regulatory evolution, and distribution transformation point to a central theme: success in the central nervous system therapeutics domain requires integrated strategy that aligns clinical differentiation with operational excellence. Companies that can translate mechanistic novelty into patient-relevant outcomes while ensuring supply continuity and payer alignment stand to create sustainable value. Conversely, firms that underestimate the operational or evidence-generation demands of contemporary payers and providers may face access barriers despite clinical promise.

Strategic clarity-rooted in segmentation-driven planning, regional nuance, and a rigorous appreciation of supply chain and policy dynamics-enables stakeholders to prioritize investments and to design partnerships that accelerate clinical and commercial milestones. The recommendations in this summary are intended to guide deliberative action: fortify supply networks, select formulation and delivery modalities that improve adherence and differentiate products, engage payers and regulators early, and integrate real-world evidence into commercialization plans. By adopting these practices, teams can better navigate the complexity of CNS markets and position novel and established therapies for durable clinical and commercial impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Central Nervous System Drugs Market, by Drug Class

  • 8.1. Analgesic
    • 8.1.1. Non-Opioid Analgesic
    • 8.1.2. Opioid Analgesic
  • 8.2. Antidepressant
  • 8.3. Antiepileptic
    • 8.3.1. Calcium Channel Blocker
    • 8.3.2. Gaba Enhancer
    • 8.3.3. Glutamate Inhibitor
    • 8.3.4. Sodium Channel Blocker
  • 8.4. Antipsychotic
    • 8.4.1. Atypical
    • 8.4.2. Typical
  • 8.5. Anxiolytic
    • 8.5.1. Benzodiazepine
    • 8.5.2. Non-Benzodiazepine
  • 8.6. Cns Stimulant
    • 8.6.1. Amphetamines
    • 8.6.2. Methylphenidate
  • 8.7. Hypnotic And Sedative
    • 8.7.1. Barbiturates
    • 8.7.2. Benzodiazepine
    • 8.7.3. Non-Benzodiazepine Hypnotics

9. Central Nervous System Drugs Market, by Dosage Form

  • 9.1. Capsule
    • 9.1.1. Extended-Release Capsule
    • 9.1.2. Standard Capsule
  • 9.2. Injectable Solution
    • 9.2.1. IM
    • 9.2.2. IV
    • 9.2.3. Subcutaneous
  • 9.3. Oral Solution
    • 9.3.1. Suspension
    • 9.3.2. Syrup
  • 9.4. Tablet
    • 9.4.1. Delayed-Release Tablet
    • 9.4.2. Extended-Release Tablet
    • 9.4.3. Standard Tablet
  • 9.5. Transdermal Patch
    • 9.5.1. Matrix Patch
    • 9.5.2. Reservoir Patch

10. Central Nervous System Drugs Market, by Patient Type

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Central Nervous System Drugs Market, by Mechanism Of Action

  • 11.1. Cholinergic
  • 11.2. Dopaminergic
  • 11.3. Gabaergic
  • 11.4. Glutamatergic
  • 11.5. Noradrenergic
  • 11.6. Serotonergic

12. Central Nervous System Drugs Market, by Therapeutic Area

  • 12.1. ADHD
  • 12.2. Alzheimer's Disease
  • 12.3. Anxiety
  • 12.4. Depression
  • 12.5. Epilepsy
  • 12.6. Insomnia
  • 12.7. Migraine
  • 12.8. Pain
  • 12.9. Parkinson's Disease
  • 12.10. Schizophrenia

13. Central Nervous System Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Central Nervous System Drugs Market, by Prescription Type

  • 14.1. Over The Counter
  • 14.2. Prescription

15. Central Nervous System Drugs Market, by Sales Model

  • 15.1. Branded
  • 15.2. Generic

16. Central Nervous System Drugs Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Central Nervous System Drugs Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Central Nervous System Drugs Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Central Nervous System Drugs Market

20. China Central Nervous System Drugs Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. AbbVie Inc
  • 21.6. Allergan plc
  • 21.7. Amgen Inc
  • 21.8. AstraZeneca plc
  • 21.9. Bayer AG
  • 21.10. Biogen Inc
  • 21.11. Bristol-Myers Squibb Company
  • 21.12. Eli Lilly and Company
  • 21.13. GlaxoSmithKline plc
  • 21.14. H. Lundbeck A/S
  • 21.15. Johnson & Johnson Services, Inc
  • 21.16. Merck & Co., Inc
  • 21.17. Neurocrine Biosciences, Inc
  • 21.18. Novartis AG
  • 21.19. Otsuka Pharmaceutical Co., Ltd
  • 21.20. Pfizer Inc
  • 21.21. Sanofi S.A.
  • 21.22. Takeda Pharmaceutical Company Ltd
  • 21.23. Teva Pharmaceutical Industries Ltd
  • 21.24. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOPAMINERGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOPAMINERGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOPAMINERGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABAERGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABAERGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABAERGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATERGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATERGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATERGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NORADRENERGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NORADRENERGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NORADRENERGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SEROTONERGIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SEROTONERGIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SEROTONERGIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADHD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADHD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADHD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIETY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIETY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIETY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INSOMNIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INSOMNIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INSOMNIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MIGRAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MIGRAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 219. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 274. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA CENTRAL